Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - Citizens JMP raised its price target on Hinge Health Inc (NYSE:HNGE) to $65.00 from $58.00 while maintaining a Market Outperform rating following the company’s second-quarter earnings report. The digital health company, currently valued at $3.76 billion, maintains a "GREAT" financial health score according to InvestingPro analysis.
The digital health company reported revenue of $139.1 million in its first quarter as a public company, exceeding consensus estimates of $125.4 million and representing 55% year-over-year growth.
Hinge Health posted billings of $196.6 million, surpassing Citizens’ estimate of $155.8 million and showing 45% year-over-year growth for the quarter ending June 2025.
The company demonstrated strong profitability with a non-GAAP operating margin of 18.8%, significantly higher than the consensus estimate of 3.1%, and delivered estimated non-GAAP earnings per share of $0.33, well above the $0.09 consensus.
Hinge Health stock rose 8% in after-hours trading following the earnings announcement and has gained approximately 63% from its IPO price of $32, outperforming the Russell 3000 index’s 9% increase over the same period. Trading at a P/E ratio of 9.86, InvestingPro analysis suggests the stock is currently trading above its Fair Value, with 8 additional key insights available to subscribers.
In other recent news, Hinge Health has been the subject of several analyst assessments following its recent public offering. Citizens JMP initiated coverage on Hinge Health with a Market Outperform rating and set a price target of $58.00. Additionally, Raymond (NSE:RYMD) James also began coverage with an outperform rating, highlighting the company’s potential for over 20% annual revenue growth over the next three years. Needham joined in with a buy rating, emphasizing Hinge Health’s leadership in the virtual musculoskeletal care market and its competitive advantages.
Truist Securities reiterated its buy rating on Hinge Health, maintaining a $48.00 price target. This reaffirmation came after a meeting with company executives and the announcement of HingeSelect, a new provider network for musculoskeletal care. The network aims to enhance Hinge Health’s service offerings using software and AI, with broader implementation expected in 2026. These developments underline the positive sentiment among analysts regarding Hinge Health’s market position and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.